Stock Events

Stock Events

BioNexus Gene Lab 

$2.61
24
+$0.09+3.57% Thursday 20:00

Statistics

Day High
2.61
Day Low
2.35
52W High
11.14
52W Low
1.94
Volume
92,200
Avg. Volume
-
Mkt Cap
4.69M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30SepExpected
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
-0
0
0.01
0.01
Expected EPS
N/A
Actual EPS
0.0017

Financials

-16.8%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
19.02MRevenue
-3.2MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BGLC. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap24.35B
Illumina provides integrated sequencing and array-based solutions for genetic and genomic analysis, directly competing in the gene sequencing space with BioNexus Gene Lab.
CRISPR Therapeutics
CRSP
Mkt Cap4.9B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the genetic engineering and modification sector, offering alternative or complementary technologies to those of BioNexus Gene Lab.
Intellia Therapeutics
NTLA
Mkt Cap1.69B
Intellia Therapeutics is a leading genome editing company that competes with BioNexus Gene Lab in the development of therapeutics based on gene editing technologies.
Editas Medicine
EDIT
Mkt Cap383.65M
Editas Medicine operates in the CRISPR gene editing space, making it a competitor by offering gene editing technologies and therapies that may overlap with or rival those of BioNexus Gene Lab.
Pacific Biosciences of California
PACB
Mkt Cap406.89M
Pacific Biosciences offers long-read sequencing technologies, competing with BioNexus Gene Lab in the genomic analysis and sequencing market.
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
Regeneron Pharmaceuticals is involved in genetic sequencing and the development of medications based on genetic insights, positioning it as a competitor in the genetic research and therapeutic development space.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.92B
Vertex Pharmaceuticals engages in the creation of drugs based on genetic insights, making it a competitor in the field of genetic disease treatment and research.
Teladoc Health
TDOC
Mkt Cap1.32B
Teladoc Health, through its acquisition of Livongo and other initiatives, is expanding into the genetic health advice and telemedicine space, indirectly competing with BioNexus Gene Lab's genetic analysis services.
Guardant Health
GH
Mkt Cap17.45B
Guardant Health specializes in cancer diagnostics through liquid biopsies, competing in the genetic testing market, particularly in the oncology segment.

About

BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Show more...
CEO
Mr. Su-Leng Tan
Employees
30
Country
United States
ISIN
US0906283066

Listings

XNAS
US
BGLC
BOATS
BOATS
BGLC.BOATS

0 Comments

Share your thoughts

FAQ

What is BioNexus Gene Lab stock price today?▼
The current price of BGLC is $2.61 USD — it has increased by +3.57% in the past 24 hours. Watch BioNexus Gene Lab stock price performance more closely on the chart.
What is BioNexus Gene Lab stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange BioNexus Gene Lab stocks are traded under the ticker BGLC.
Is BioNexus Gene Lab stock price growing?▼
BGLC stock has risen by +21.96% compared to the previous week, the month change is a +24.88% rise, over the last year BioNexus Gene Lab has showed a -9.06% decrease.
What is BioNexus Gene Lab market cap?▼
Today BioNexus Gene Lab has the market capitalization of 4.69M
What were BioNexus Gene Lab earnings last quarter?▼
BGLC earnings for the last quarter are 0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is BioNexus Gene Lab revenue for the last year?▼
BioNexus Gene Lab revenue for the last year amounts to 19.02M USD.
What is BioNexus Gene Lab net income for the last year?▼
BGLC net income for the last year is -3.2M USD.
How many employees does BioNexus Gene Lab have?▼
As of June 20, 2026, the company has 30 employees.
In which sector is BioNexus Gene Lab located?▼
BioNexus Gene Lab operates in the Materials sector.
When did BioNexus Gene Lab complete a stock split?▼
The last stock split for BioNexus Gene Lab was on April 07, 2025 with a ratio of 1:10.
Where is BioNexus Gene Lab headquartered?▼
BioNexus Gene Lab is headquartered in Kuala Lumpur, United States.